Anticoagulant Therapy in Comorbidal Patients With Different Forms of Fibrillation of Auricles (Retrospective Hospital Analysis)

Рубаненко, О. А.

doi:10.20333/2500136-2017-2-71-76

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Варфарин и другие антагонисты витамина К (АВК) являются высокоэффективными непрямыми пероральными антикоагулянтами, но их возможности ограничены узким терапевтическим окном, взаимодействием с другими лекарствами и пищевыми продуктами, а также необходимостью частого мониторинга показателя международного нормализованного отношения (МНО) [1][2][3]. Прямые пероральные антикоагулянты, включая дабигатран (прямой ингибитор тромбина) и прямые ингибиторы фактора Ха, включая ривароксабан, апиксабан, эдоксабан и бетриксабан, были разработаны для преодоления некоторых ограничений, связанных с применением АВК, позволяющих применять фиксированные дозировки без рутинного терапевтического мониторинга.…”

Section: Introductionunclassified

Pharmacokinetics and Pharmacogenetics of Apixaban

Savinova

Добродеева

Петрова

et al. 2020

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Apixaban is oral anticoagulant, it is widely used in prevention of stroke in non-valvular atrial fibrillation and treatment of deep vein thrombosis and pulmonary embolism. Its main mechanism of action is through reversible inhibition of factor Xa. It specifically binds and inhibits both free and bound factor Xa which ultimately results in reduction in the levels of thrombin formation. Apixaban is mainly metabolized by CYP3A4 with minor contributions from CYP1A2, CYP2C8, CYP2C9, CYP2C19 and CYP2J2 isoenzymes. Some of the major metabolic pathways of apixaban include o-demethylation, hydroxylation, and sulfation, with o-demethylapixabansulphate being the major metabolite. The aim of this review is analysis of associated researches of single nucleotide variants (SNV) of CYP3A5 and SULT1A1 genes and search for new candidate genes reflecting effectiveness and safety of apixaban. The search for full-text publications in Russian and English languages containing key words “apixaban”, “pharmacokinetics”, “effectiveness”, “safety” was carried out amongst literature of the past twenty years with the use of eLibrary, PubMed, Web of Science, OMIM data bases. Pharmacokinetics and pharmacogenetics of apixaban are considered in this review. The hypothesis about CYP и SULT1A enzymes influence on apixaban metabolism was examined. To date, numerous SNVs of the CYP3A5 and SULT1A1 genes have been identified, but their potential influence on pharmacokinetics apixaban in clinical practice needs to be further studies. The role of SNVs of other genes encoding beta-oxidation enzymes of apixaban (CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2J2) and transporter proteins (ABCB1, ABCG2) in its efficacy and safety are not well understood, and ABCB1 and ABCG2 genes may be potential candidate genes for studies of the drug safety.

show abstract

Section: Introductionunclassified